These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 8563482)

  • 1. Medullary thyroid carcinoma: recent advances and management update.
    Marsh DJ; Learoyd DL; Robinson BG
    Thyroid; 1995 Oct; 5(5):407-24. PubMed ID: 8563482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
    González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
    Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
    Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of medullary thyroid cancer.
    Modigliani E; Franc B; Niccoli-sire P
    Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Dec; 14(4):631-49. PubMed ID: 11289739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families.
    Marsh DJ; McDowall D; Hyland VJ; Andrew SD; Schnitzler M; Gaskin EL; Nevell DF; Diamond T; Delbridge L; Clifton-Bligh P; Robinson BG
    Clin Endocrinol (Oxf); 1996 Feb; 44(2):213-20. PubMed ID: 8849577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary.
    Klein I; Esik O; Homolya V; Szeri F; Váradi A
    J Endocrinol; 2001 Sep; 170(3):661-6. PubMed ID: 11524247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
    Uchino S; Noguchi S; Yamashita H; Sato M; Adachi M; Yamashita H; Watanabe S; Ohshima A; Mitsuyama S; Iwashita T; Takahashi M
    Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
    Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
    Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
    Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
    Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas.
    Shan L; Nakamura M; Nakamura Y; Utsunomiya H; Shou N; Jiang X; Jing X; Yokoi T; Kakudo K
    Jpn J Cancer Res; 1998 Sep; 89(9):883-6. PubMed ID: 9818022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.